Eric Hughes
Vice President, Global R&D and Chief Medical Officer, Teva Pharmaceuticals
Dr. Eric A. Hughes, MD, PhD, was appointed Executive Vice President, Global R&D and Chief Medical Officer at Teva Pharmaceuticals in August 2022. He is an accomplished scientist and licensed physician with specialty training in infectious diseases and immunology paired with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies.
At Teva Pharmaceuticals, Dr. Hughes oversees a global R&D organization of ~3,700 colleagues responsible for the discovery and development of innovative medicines and high-quality generics and combination products that provide meaningful therapeutic benefit to patients worldwide. With an innovative medicines pipeline focused on immunology and neuroscience, a diverse portfolio of generic products covering all major therapeutic categories and a broad early stage biosimilars pipeline, Teva Pharmaceuticals' Global R&D team uses sincere understanding of patient experience, deep scientific knowledge and a strong understanding of diverse technologies to discover new pathways, spark unique connections and make bold discoveries to step up innovation.
Prior to Teva Pharmaceuticals, Dr. Hughes was Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals in Boston, Massachusetts, in the U.S. From 2015 to 2021, he was Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis in Switzerland, ultimately responsible for leading all clinical development activities and biostatistician talent across multiple therapeutic areas and for expanding development in China.
During the pandemic in 2020 and 2021, Dr. Hughes served as Co-Chair of the Therapeutics Clinical Working Group for The Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership at The National Institutes of Health.
Dr. Hughes launched his career in the pharmaceutical industry in 2004 at Bristol Myers-Squibb Company (BMS) and moved to Schering-Plough Research Institute in 2006. Beginning in 2009, he spent a year at Merck Research Laboratories as the Director of Clinical Research for Hepatology before returning to BMS in 2010 where his career there culminated in 2015 as Head of Virology, Fibrotic Diseases, Genetically Defined Diseases, Autoimmunity, and Cardiology Discovery Medicine, Exploratory Clinical & Translational Research.
Dr. Hughes earned his MD and PhD at Yale School of Medicine. He completed his medical residency with the Department of Internal Medicine at Yale New Haven Hospital/Yale University School of Medicine, and a Fellowship in Infectious Diseases at the Yale University School of Medicine. He is a prolific and widely published scientist, co-authoring more than 50 articles in peer-reviewed scientific journals, and has a deep passion for helping patients.
